Related Experiment Video
Updated: Jun 14, 2026

Long-term Behavioral and Reproductive Consequences of Embryonic Exposure to Low-dose Toxicants
Published on: March 6, 2018
Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100
D R Illingworth1, F Vakar, R W Mahley
1Department of Medicine, Oregon Health Sciences University, Portland 97201-3098.
Insights
Familial defective apolipoprotein B-100 (FDB) is a genetic condition causing high cholesterol. Lovastatin treatment effectively lowered LDL cholesterol in FDB patients, suggesting statins are a viable treatment option.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Pharmacology
Background:
- Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant disorder.
- It is characterized by hypercholesterolemia due to a specific amino acid substitution in apoprotein B-100.
- This substitution results in low-density lipoprotein (LDL) particles with impaired binding to LDL receptors.
Purpose of the Study:
- To evaluate the efficacy of lovastatin in treating hypercholesterolemia in patients with FDB.
- To determine the dose-dependent response to lovastatin in this patient population.
Main Methods:
- A study involving 12 hypercholesterolemic patients from 10 unrelated families with FDB.
- Patients were treated with either 20 mg or 40 mg of lovastatin daily.
- Plasma LDL cholesterol levels were measured before and after treatment.
Main Results:
- Treatment with 20 mg of lovastatin daily resulted in a 21.5% decrease in LDL cholesterol.
- A higher dose of 40 mg daily led to a more significant reduction of 32.1% in LDL cholesterol.
- Both dosages showed a positive impact on hypercholesterolemia in FDB patients.
Conclusions:
- Hypercholesterolemia associated with FDB can be effectively managed with statin therapy.
- Lovastatin demonstrates a dose-dependent efficacy in reducing LDL cholesterol levels in FDB patients.
- These findings support the use of statins as a therapeutic strategy for FDB.
Abstract:
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant disorder associated with hypercholesterolaemia in which an aminoacid substitution in apoprotein B-100 leads to low-density lipoprotein (LDL) particles which have defective binding to the LDL receptor. All known patients are heterozygous, and their plasma contains normal and poorly binding LDL particles. 12 hypercholesterolaemic patients from 10 unrelated families with FDB were treated with lovastatin. In 6 patients treated with 20 mg lovastatin daily, LDL cholesterol decreased by 21.5% from 6.23 to 4.89 mmol/l (95% confidence interval 0.74, 1.96 mmol/l), whereas it fell by 32.1%, from 6.99 to 4.81 mmol/l (95% CI 1.55, 2.70 mmol/l), in 9 patients who received 40 mg daily. These results indicate that the hypercholesterolaemia of FDB may respond to treatment with statins.
Related Concept Videos
Lipids: Dietary Sources and Requirements
Vitamins
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Inborn Errors of Metabolism
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

